Kestra Medical (KMTS) Director Kevin Reilly Sells Shares, Receives Award

What Happened
Kevin C. Reilly, a director of Kestra Medical Technologies, sold 2,932 shares in an open-market/privately executed sell-to-cover transaction on 2026-09-08 for a weighted average price of $25.13, totaling $73,677. The next day (2026-09-09) he was reported as receiving 7,217 restricted stock units (RSUs) in a grant/award transaction; no dollar amount is reported for the grant on the Form 4.

Key Details

• Transaction dates: Sale 2026-09-08; Grant 2026-09-09. Form 4 filed 2026-09-10.
• Sale details: 2,932 shares disposed; weighted average price $25.13; price range reported $24.91–$25.35; total proceeds reported $73,677.
• Grant details: 7,217 RSUs acquired (each RSU entitles holder to one common share); dollar value not reported on the Form 4. RSUs vest on 2027-09-09, subject to continued service.
• Reason for sale: Reported as a nondiscretionary sell-to-cover to satisfy tax withholding on vesting/settlement of RSUs.
• Shares owned after transaction: Not specified in the filing.
• Filing timeliness: Form 4 filed 2026-09-10 (covers transactions on 9/8 and 9/9).

Context
The sale was a routine sell-to-cover to satisfy tax withholding tied to equity compensation and is different from an intentional market-timed disposition. The subsequent entry reports a standard grant of RSUs that will vest next year if the director remains in service; awards like this are compensation, not an outright purchase indicating personal bullishness.